<code id='6466BAAB72'></code><style id='6466BAAB72'></style>
    • <acronym id='6466BAAB72'></acronym>
      <center id='6466BAAB72'><center id='6466BAAB72'><tfoot id='6466BAAB72'></tfoot></center><abbr id='6466BAAB72'><dir id='6466BAAB72'><tfoot id='6466BAAB72'></tfoot><noframes id='6466BAAB72'>

    • <optgroup id='6466BAAB72'><strike id='6466BAAB72'><sup id='6466BAAB72'></sup></strike><code id='6466BAAB72'></code></optgroup>
        1. <b id='6466BAAB72'><label id='6466BAAB72'><select id='6466BAAB72'><dt id='6466BAAB72'><span id='6466BAAB72'></span></dt></select></label></b><u id='6466BAAB72'></u>
          <i id='6466BAAB72'><strike id='6466BAAB72'><tt id='6466BAAB72'><pre id='6466BAAB72'></pre></tt></strike></i>

          focus

          focus

          author:focus    Page View:99
          Brain cancer
          Michelle Monje/Stanford University/NIH

          Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

          The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

          advertisement

          “We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          Biden’s NIH nominee is languishing in Congress
          Biden’s NIH nominee is languishing in Congress

          PublichealthadvocatesworrythefeudbetweenPresidentBidenandSen.BernieSanderscouldsqueezeoutanotherwise

          read more
          Malaria cases in Florida and Texas: Here’s what you need to know
          Malaria cases in Florida and Texas: Here’s what you need to know

          MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

          read more

          The U.S. needs a new definition of substance use “recovery”

          Adobe“WhenIuseaword,”oneof19thcenturyBritishauthorandmathematicianLewisCarroll’scharactersoncesaid,“